Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Mefloquine/mirtazapine/natalizumab

Progressive multifocal leukoencephalopathy and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sugimoto T, et al. A case of natalizumab-associated progressive multifocal leukoencephalopathy followed by immune reconstitution inflammatory syndrome with difficulty in the timing of immunotherapy. Clinical and Experimental Neuroimmunology 14: 110-115, No. 2, 18 Oct 2022. Available from: URL: http://doi.org/10.1111/cen3.12734 Sugimoto T, et al. A case of natalizumab-associated progressive multifocal leukoencephalopathy followed by immune reconstitution inflammatory syndrome with difficulty in the timing of immunotherapy. Clinical and Experimental Neuroimmunology 14: 110-115, No. 2, 18 Oct 2022. Available from: URL: http://​doi.​org/​10.​1111/​cen3.​12734
Metadaten
Titel
Mefloquine/mirtazapine/natalizumab
Progressive multifocal leukoencephalopathy and lack of efficacy: case report
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51555-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Vincristine

Case report

Propofol

Case report

Camrelizumab